Travere Therapeutics received full U.S. Food and Drug Administration approval on April 14, 2026 for its dual endothelin‑A and angiotensin‑II receptor antagonist, FILSPARI (sparsentan), to treat focal segmental glomerulosclerosis (FSGS). The approval expands FILSPARI’s indication beyond its existing approval for IgA nephropathy and establishes the drug as the first and only FDA‑approved therapy for FSGS.
Ligand Pharmaceuticals, which holds a 9% royalty on worldwide net sales of FILSPARI, views the new indication as a key driver of long‑term royalty growth. The company’s 2025 royalty revenue grew 48% year‑over‑year, largely powered by FILSPARI sales in its IgA nephropathy indication, and Ligand reaffirmed its 2026 guidance for royalty revenue of $200–$225 million, with the FSGS approval expected to contribute significantly to that target.
The approval was based on the Phase 3 DUPLEX study, which demonstrated a 48% reduction in proteinuria for FILSPARI versus 27% for irbesartan in patients without nephrotic syndrome at 108 weeks. The overall study population showed a 46% reduction versus 30% for irbesartan. The dual mechanism of action—blocking both endothelin‑A and angiotensin‑II receptors—targets complementary profibrotic and inflammatory pathways implicated in progressive proteinuric kidney injury.
FSGS represents a substantial unmet medical need; prior to this approval patients relied on off‑label therapies such as steroids and immunosuppressants, which carry significant side‑effect burdens. The U.S. addressable population for FILSPARI in FSGS without nephrotic syndrome is estimated at more than 30,000 individuals, and the broader FSGS population is projected to exceed 70,000 as the disease prevalence rises.
"Today marks a historic milestone for people living with FSGS, who for the first time have an FDA‑approved medicine for this rare and devastating condition," said Eric Dube, Ph.D., President and CEO of Travere Therapeutics. "This approval reflects years of perseverance and our belief that those living with FSGS deserve better." Todd Davis, CEO of Ligand Pharmaceuticals, added, "We congratulate Travere for achieving this incredible milestone, which builds on other recent successes for FILSPARI. As the first and only FDA‑approved medicine indicated for this rare and serious condition, FILSPARI offers new hope for kidney patients. This approval positions FILSPARI to be a key driver of long‑term royalty growth for Ligand in 2026 and beyond."
The approval removes a regulatory hurdle that had delayed the drug’s launch in this indication, allowing Travere to capture revenue from a sizable rare‑disease market. With FILSPARI’s dual‑mechanism profile and proven proteinuria‑reducing efficacy, the company is poised to become the market leader in FSGS treatment, while Ligand’s royalty stream is expected to grow steadily as the drug gains market share in both the IgA nephropathy and FSGS indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.